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Depletion of mitochondrial
protease OMA1 alters proliferative
properties and promotes metastatic
growth of breast cancer cells
Amita Daverey1, Roman M. Levytskyy2, Kimberly M. Stanke1, Martonio Ponte Viana2,
Samantha Swenson2, Stephen L. Hayward1, Madhusudhanan Narasimhan3,
Oleh Khalimonchuk 2,4,5,6 & Srivatsan Kidambi 1,5,6,7,8,9
Metastatic competence of cancer cells is influenced by many factors including metabolic alterations
and changes in mitochondrial biogenesis and protein homeostasis. While it is generally accepted that
mitochondria play important roles in tumorigenesis, the respective molecular events that regulate
aberrant cancer cell proliferation remain to be clarified. Therefore, understanding the mechanisms
underlying the role of mitochondria in cancer progression has potential implications in the development
of new therapeutic strategies. We show that low expression of mitochondrial quality control protease
OMA1 correlates with poor overall survival in breast cancer patients. Silencing OMA1 in vitro in patientderived metastatic breast cancer cells isolated from the metastatic pleural effusion and atypical ductal
hyperplasia mammary tumor specimens (21MT-1 and 21PT) enhances the formation of filopodia,
increases cell proliferation (Ki67 expression), and induces epithelial-mesenchymal transition (EMT).
Mechanistically, loss of OMA1 results in alterations in the mitochondrial protein homeostasis, as
reflected by enhanced expression of canonic mitochondrial unfolded protein response genes. These
changes significantly increase migratory properties in metastatic breast cancer cells, indicating that
OMA1 plays a critical role in suppressing metastatic competence of breast tumors. Interestingly, these
results were not observed in OMA1-depleted non-tumorigenic MCF10A mammary epithelial cells. This
newly identified reduced activity/levels of OMA1 provides insights into the mechanisms leading to breast
cancer development, promoting malignant progression of cancer cells and unfavorable clinical outcomes,
which may represent possible prognostic markers and therapeutic targets for breast cancer treatment.
Breast cancer is a complex disease affecting over 180,000 women annually involving a continuously changing
phenotype and microenvironment leading to differences in the gene and protein profile of the neoplasm 1–5.
Metastasis to vital organs including lungs, liver, bone, and brain is a major cause for breast cancer-related deaths6.
Two main processes, migration and invasion, mediate the metastatic activity of tumor cells. Mounting evidence
indicates that altered mitochondrial functions play a significant role(s) in the regulation of tumor cell biology and
are likely involved in tumor progression including metastasis7–12. Growing evidence indicates that mitochondrial
integrity is central to cancer cell physiology, particularly with regard to energy production and cell survival in the
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highly dynamic tumor environment. Perturbations to mitochondrial integrity by mutations or functional decline
lead to mitochondrial dysfunction, potentially impacting physiological properties of neoplastic cells. Many
cancer cells undergo the metabolic adaptation known as aerobic glycolysis, or Warburg effect; which involves
enhanced utilization of glucose or pyruvate for anabolic processes underpinning rapid proliferation12–14. These
cells also rely on glutamate anaplerosis to replenish the tricarboxylic acid (TCA) cycle with pyruvate. Alterations
in mitochondrial function and the subsequent metabolic reprogramming are now being recognized as important
hallmarks of malignancy and metastasis12. To date, several studies reported a loss of key mitochondrial proteins
in various cancers, including breast cancer15–17. However, the mechanisms by which mitochondrial malfunction
contributes to cancer progression remain far from clear.
Mitochondria are highly dynamic organelles whose form and shape are regulated through two critical processes: fission and fusion. The dynamic nature of mitochondrial networks allows the adjustment of mitochondrial
morphology and metabolism to specific cellular processes and is also essential for mitochondrial protein quality control (MQC)18–20. MQC comprises a unique and conserved set of interrelated mechanisms critical for the
organelle’s health21. Recent reports implicate several MQC modules in development and progression of various
cancers22. For instance, elevated activities of ATP-driven proteases Lon proteases (LONP) and mitochondrial
unfoldase-peptidase complex ClpXP have been shown to correlate with tumor development and progression23,24.
Consequently, inhibition of these proteases has been proposed as a potential therapeutic strategy in patients with
lymphoma and acute myeloid leukemia, respectively22,25. Activities of several other MQC proteases have been suggested to prevent malignant progression26,27; however, the molecular details of this process remain to be clarified.
Overlapping With The m-AAA Protease 1 (OMA1) is a conserved metallopeptidase that has recently emerged
as a critical regulator of metabolic homeostasis19,28–30, mitophagy31, and apoptosis32. At least in part, such functional versatility is attributed to the enzyme’s ability to process the GTPase, Optic Atrophy Protein 1 (OPA1), and
thus rapidly modulate the mitochondrial network31. Recently, we discovered that OMA1-deficient mouse embryonic fibroblasts exhibit increased aerobic glycolysis upon culturing conditions that require maximal bioenergetic
output33. Intriguingly, results of the Human Protein Atlas Consortium initiative15–17 report low OMA1 protein
levels in breast and testicular cancer tissues, as well as in lymphomas. However, whether OMA1 plays a role in the
development and progression of breast adenocarcinoma is unknown.
In the present study, we report that depletion of OMA1 in stable, patient-derived breast cancer cells isolated
from the metastatic pleural effusion (21MT-1) and atypical ductal hyperplasia (21PT) increased expression of the
canonical mitochondrial unfolded protein response (UPRmt) markers, cell spreading, and filopodia formation.
Moreover, sustained silencing of OMA1 resulted in a large proportion of cells exhibiting mesenchyme-like morphology, reduced proliferation, and enhanced migratory properties indicative of the epithelial-mesenchyme transition (EMT). Consistent with enhanced metastatic abilities of the OMA1-depleted breast cancer cells, we observed
a significant upregulation of mesenchymal markers and decreased expression of epithelial markers at both the
gene and protein levels. Together with bioinformatics data indicating that breast cancer patients with low, EMT
markers-correlating OMA1 expression have a shorter survival time, our findings led us to conclude that impaired
MQC function through OMA1 deficit can regulate malignancy and metastatic progression in breast cancer.

Results

OMA1 expression levels correlate with patient survival in breast cancer. To determine if OMA1
expression was related to patient prognosis, we performed survival risk prediction using survival database to
evaluate the correlation between OMA1 expression levels and overall survival rates in breast cancer patients
(Fig. 1). OMA1 mRNA expression is represented as batch normalized/merged from Illumina HiSeq_RNASeqV2
syn4976369 generated by “The Cancer Genome Atlas (TCGA)”. Out of 1084 breast cancer patient samples, the
expression data were available for 1082 samples. Normal distribution across the dataset is visualized with box and
whisker plots, shown as 25th (316.3) and 75th (521.5) percentiles with a median of 404.8 (Fig. 1A). Based on this
data and reports from Geng et al.31 and Bertucci et al.32, we dichotomized the samples into low OMA1 and high
OMA1 expressing group with values up to 25th percentile (≤316.3) comprising the former and those equaling and
above the 25th percentile (316.3) into the latter.
To better understand the involvement of OMA1 in breast cancer, we next determined the survival of subjects
in the low and high OMA1 expressing subsets. Out of 1084 samples, 1078 had all the necessary details such
as OMA1 gene expression, overall survival months, and vital status to perform Kaplan-Meier survival analysis
(Fig. 1B). In these cohort of 1078 samples that had all the available survival data and applying the above dichotomy rule, 270 samples stratified into low and 808 samples segregated into high OMA1 expressing subset. Survival
plot was generated using the OMA1-segregated samples. It was found that the OMA1-low expressing patients
had poor survival when compared to OMA1-high expressing patients. The number of events (deaths) was ~17%
(46/270) in the low-OMA1 expressing group, while the number of events in the high-OMA1 expressing group is
only ~13% (105/808), indicating that low OMA1 expression increased the probability of mortality by 31% when
compared to the high-OMA1 expressing subset. In parallel, the median survival was 114.06 and 130.06 months in
OMA1-low and –high expressing patients, respectively. In other words, the OMA1-low expressing patients displayed a ~14% decrease in the median survival when compared to OMA1-high expressing subjects. These results
suggest that a low OMA1 expression could be associated with poor overall survival in breast cancer.
Typically, epithelial to mesenchymal transition (EMT) program is a process where cells lose epithelial traits
(decreased marker expression) and acquire mesenchymal characteristics (increased marker expression) that is
tightly associated with malignancy, invasion, metastasis, and poor outcome34–36. While this generally applies to
many transformed cells, we posited that attenuation of OMA1 might facilitate EMT program. To that end, we
used GEPIA (Gene Expression Profiling Interactive Analysis), a web-based tool (uses TCGA and GTEx dataset)
to determine the relationship between aberrant OMA1 mRNA levels with the expression of some of the common
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Figure 1. OMA1 expression levels correlate with patient survival in breast cancer. (A) OMA1 mRNA
expression is represented as batch normalized/merged from Illumina HiSeq_RNASeqV2 syn4976369 generated
by The Cancer Genome Atlas (TCGA). Out of 1084, the expression data was available for 1082 samples. Normal
distribution across the dataset is visualized with box and whisker plots, shown as 25th (316.3) and 75th (521.5)
percentiles with a median of 404.8. From this a 316.3 expression cut-off was assigned to evaluate the Survival.
(B) Out of 1084 samples, only 1078 patients had all the information required for Survival analysis. Among
these 1078 patients that had all the information, based on the OMA1 expression (at or below 25th percentile
assigned as low and above 25th percentile assigned as high) was used to compute the survival analysis. It
was found that the patients with low OMA1 expression had poor survival when compared to patients with
high OMA1-expression. The number of events (deaths) were ~17% (46/270) in the group with low OMA1
expression, while the number of events in the group with high OMA1 expression is only ~13% (105/808), which
comprises a ~31% increase in the mortality in the group expressing low levels of OMA1 in comparison to the
group expressing high levels of OMA1. (C) Pearson’s correlation analysis of the mRNA expression datasets for
OMA1 and epithelial marker genes-MUC1, CDH1, EPCAM using the input, TCGA_Tumor (BRCA Tumor)
and TCGA_Normal (BRCA_Normal). (D) Pearson’s correlation analysis of the mRNA expression datasets for
OMA1 and mesenchymal marker genes-TWIST1, ZEB1, Fibronectin (FN1) using the input, TCGA_Tumor
(BRCA Tumor) and TCGA_Normal (BRCA_Normal).

EMT marker genes in human breast cancer (Fig. 1C,D). Pearson correlation analysis of the mRNA expression
datasets for OMA1 and epithelial marker genes such as MUC1, CDH1, and EPCAM using the input, TCGA_
Tumor (BRCA Tumor) and TCGA_Normal (BRCA_Normal) revealed a statistically significant positive correlation with the OMA1 mRNA expression (P = 1.3e−12, R = 0.2 for MUC1; P = 1.1e−06, R = 0.14 for E-cadherin
(CDH1); P = 0.00087, R = 0.096 for EPCAM) in the TCGA_BRCA dataset when compared to the TCGA_Normal
dataset (Fig. 1C). This implies that OMA1 presence could promote epithelial signals and trait. In other words,
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depletion of OMA1 can be correlated to a loss of epithelial morphology. Similar correlation analysis was conducted for mRNA expression datasets for OMA1 and mesenchymal marker genes such as TWIST1, ZEB1, and
Fibronectin (FN1) using the input, TCGA_Tumor (BRCA Tumor) and TCGA_Normal (BRCA_Normal) with
Pearson’s statistical test (Fig. 1D). In contrast, to the changes observed in epithelial markers, all the analyzed
mesenchymal markers are negatively correlated with OMA1 mRNA expression as can be seen from the negative R values (−0.14, −0.05, −0.074 for TWIST1, ZEB1, and Fibronectin (FN1), respectively) from the TCGA_
BRCA vs TCGA_Normal dataset comparison. Moreover, OMA1 expression displayed significant difference with
the TWIST1 (P = 9.0e−07) and FN1 expression (P = 0.11) with ZEB1 tending towards significance (P = 0.081).
This denotes that the presence of OMA1 could repress mesenchymal signals and phenotype. In other words,
the decreased OMA1 expression can be correlated to a gain in mesenchymal characteristics. These clinical data
demonstrates that attenuated OMA1 levels in human breast cancer patients are correlated to the molecular gene
signatures buttressing EMT, a well-established hallmark of invasion/metastasis. Importantly, to the best of our
knowledge, this is the first study that has evaluated the clinical value of OMA1 in breast cancer, particularly in the
context of EMT process.

OMA1-deficient cells exhibit signs of metabolic reprogramming. Our recent study revealed that
upon culturing in low glucose medium, OMA1-deficient mouse embryonic fibroblasts (MEFs) are compromised
in their ability to maximize their bioenergetic output and appear to rely on compensatory aerobic glycolysis, as
indicated by an increased extracellular acidification rate ([28] and Fig. 2A). This observation likely reflects partial
metabolic reprogramming and suggests that oma1−/− MEFs are probably more reliant on anaplerotic metabolism.
As such, these cells are expected to replenish their citrate levels through enhanced utilization of glutamine that is
metabolized via reductive carboxylation – enzymatic conversion of glutamine to glutamate, which is then modified to α-ketoglutarate, followed by its conversion to oxaloacetate and then citrate [29, 30]. Thus, OMA1-deficient
cells are expected to be more sensitive to inhibition of glutaminase (GLS) – a key enzyme mediating the first step
in the above chain of reactions. To test this postulate, we compared the proliferation of wild type and oma1−/−
cells cultured in either low glucose or galactose-containing medium in the presence or absence of 10 μM bis-2-(5phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) – a specific small molecule inhibitor of GLS. While
the proliferation of the cells in question was nearly identical under normal conditions, oma1−/− MEFs proliferated
at much slower rates than wild type cells in the presence of BPTES (Fig. 2B). These observations prompted us
to examine the ability of the WT and oma1−/− MEFs to re-enter the proliferative cycle after aging-induced quiescence, a process known to require normal mitochondrial function [31]. Contact-inhibited quiescent WT and
oma1−/− MEFs were cultured for 7 days with fresh medium added every 2 days. Following such incubation, the
proliferative properties of these post-quiescent cells were tested. While growth characteristics and morphology
of the young WT and oma1−/− cells were virtually indistinguishable (Fig. 2C), the post-quiescent oma1−/− MEFs
formed filapodia -like structures (Fig. 2C,D) and proliferated significantly faster than control MEFs (Fig. 2E).
Likewise, the post-quiescent growth of oma1−/− MEFs was characterized by enhanced cell spreading when
compared to the wild type control. Moreover, consistent with the observed filapodia structures, post-quiescent
oma1−/− MEFs displayed abnormal actin distribution patterns (Fig. 2F) resembling rearrangements reported in
neoplasms [32]. These results further highlight metabolic and morphological alterations associated with proliferative activity in OMA1-deficient mammalian cells.
Loss of OMA1 causes filopodia formation and mitochondrial fragmentation in human breast
adenocarcinoma cell lines. Alteration of focal adhesions is a hallmark of tumorigenesis [32]. The results

of our analyses in MEFs suggest that loss of OMA1 may be related to neoplastic development and/or progression. Moreover, OMA1 protein levels were reported to be extremely low in breast and testicular cancer tissues,
as well as lymphomas15–17. We thus hypothesized that OMA1 function may be attenuated in these cancers and
such a setting could be an important contributor to malignancy. To test this hypothesis, we generated stable
knockdowns of OMA1 in non-tumorigenic breast epithelial cells (MCF10A) and patient-derived breast cancer
cells isolated from metastatic pleural effusion mammary tumor specimen (21MT-1) cells using OMA1-specifc
shRNAs. Immunoblotting with an anti-OMA1 antibody confirmed efficient depletion of the protease in cells
expressing OMA1 shRNA but not the scrambled control (Fig. 3A and Supplementary Fig. S1). Transfection
of 21MT-1 cells with OMA1-targeting shRNAs caused over 80% reduction in endogenous OMA1 protein as
compared to control cells transfected with scrambled shRNAs. Microscopic images of OMA1-depleted 21MT-1
(hereafter referred to as OM.21) cells revealed enhanced filopodia formation as early as 24 hours of culture
that was even more pronounced after 48 hours (Fig. 3B,C and Supplementary Fig. S2). Remarkably, this was
not the case for OMA1-depleted MCF10A cells (designated OM.10 A; Fig. 3B). Also, OM.21 cells demonstrated
higher proliferation rates compared to control 21MT-1 cells while no significant change in proliferation rate was
observed in OM.10A and control MCF10A cells (Fig. 3D,E). Strikingly, these findings parallel our observations in
oma1−/− MEFs. To further extend these findings in other cancer cells, we generated stable knockdowns of OMA1
in patient-derived breast cancer cells isolated from atypical ductal hyperplasia (21PT) using OMA1-specific shRNAs. Immunoblotting with an anti-OMA1 antibody confirmed a robust depletion of the endogenous levels of this
protease by about 80% in cells expressing OMA1 shRNA when compared to control (Supplementary Fig. S3A).
Like 21MT-1, an enhanced filopodia formation was observed as early as 24 hours of culturing the OMA1-depleted
21PT (hereafter OP.21) cells, while this effect was more pronounced after 48 hours of culturing (Supplementary
Fig. S3B–D). These observations replicate our findings in the 21MT-1 cells.
To probe and visualize the effect of OMA1 knockdown on mitochondrial morphology and integrity, we
imaged the mitochondria of OMA1-silenced 21MT-1 cells using the fluorescent stain Mitotracker FM (Fig. 4A).
A typical fiber-like morphology was observed in control 21MT-1 cells indicating healthy mitochondria. In contrast, a slightly more dense or bulky mitochondrial network with perinuclear clustering was observed in OM.21
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Figure 2. Loss of OMA1 alters metabolic and proliferative properties of mouse embryonic fibroblasts.
(A) Extracellular acidification rates (ECAR) in wild type and oma1−/− mouse embryonic fibroblasts under basal,
FCCP-stimulated, and glycolysis-ablating (2-DG) conditions. Cells were cultured in the media containing 10 mM
glucose. Data are shown as mean values of 3 independent experiments ± S.E.M.; **p < 0.01, by unpaired t-test.
(B) Growth rate of wild type (WT) and oma1−/− MEF cells under conditions of glutamate pathway inhibition
by BPTES. Cells were cultured in the 10 mM galactose-containing medium with (left panel) or without (right
panel) 10 μM BPTES for the indicated periods of time and the number of viable cells at each time point has
been assessed. Data represent the mean ± S.D. (n = 3 biological replicates); **p < 0.01, by unpaired t-test. (C)
Live phase contrast images of MEF WT and oma1−/− cells at 2 days after seeding in normal culture conditions
and after overgrowth for 7 days at 100% confluence. Unlike the WT cells, post-quiescent oma1−/− MEFs exhibit
characteristic filopodia-like protrusions (white arrows) after overgrowth. (D) The prevalence of cells with
protrusions was analyzed in WT and oma1−/− MEF cells two days after re-seeding on 6-well plates after one
week of growth at 100% confluence. Each well was randomly imaged in 2–3 fields of view, each containing 15–50
cells. In the randomly chosen imaging fields, the number of cells with long filopodia and cells with normal
filopodia were counted. The data was plotted as a scatter plot where each point represents percentage of cells
with long filopodia of total cells in one field of view. (E) Proliferation of MEF WT and oma1−/− cells seeded
after overgrowth of 7 days at 100% confluence. Data represent the mean ± S.D. of n = 3 biological replicates;
**p < 0.01. (F) Paraformaldehyde-fixed WT and oma1−/− MEF cells on 2nd day after seeding post-overgrowth
of 7 days at 100% confluence. Samples were stained for Actin with Alexa Fluor 488-conjugated phalloidin and
imaged by confocal microscopy. The arrows mark rearranged actin patches. Scale bar, 20 μm.

cells (Fig. 4A). In addition to differences in the spatial distribution and clustering of the mitochondrial reticulum
seen in the OM.21 cells, the mitochondria within the clusters appeared to be slightly thicker and shorter segments
in comparison to control. Such changes in mitochondrial network morphology likely reflect alterations in the
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Figure 3. OMA1 depletion in metastatic breast cancer cells promotes filopodia formation. (A) The top panel
shows a representative Western blot of extracts from the metastatic pleural effusion mammary tumor 21MT-1
cells and MCF10A cells before and after transfection with either scrambled shRNA (control) or shRNA directed
against OMA1 (OM.21 and OM.10 A). Steady-state levels of the protease were detected by immunoblotting with
anti-OMA1. The GAPDH blots served as a loading control. (B) Live phase contrast images of 21MT-1 cells and
MCF10A cells before and after transfection with scrambled shRNA (control) or shRNA directed against OMA1
(OM.21 and OM.10A) at 24 h and 48 h after seeding in normal culture conditions. Unlike the control cells,
OM.21 cells exhibit characteristic filopodia-like structures (black arrows). The arrows indicate filopodia. Scale
bar, 20 μm. (C) The prevalence of cells with protrusions was analyzed in 21MT-1 cells and OM.21 cells two days
after re-seeding on 6-well plates after one week of growth at 100% confluence. Each well was randomly imaged
in 3–4 fields of view, each containing 40–75 cells. In the randomly chosen fields of view, the number of cells
with long filopodia and cells without these structures were counted. The data was plotted as a scatter plot where
each point represents percentage of cells with long filopodia of total cells in one field of view. (D) Proliferation
of 21MT-1 WT and OM.21 cells seeded after overgrowth of 7 days at 100% confluence. Data represent the
mean ± S.D. of n = 3 biological replicates; *p < 0.05, ***p < 0.001. (E) Proliferation of MCF10A WT and
OMA.10 A cells seeded after overgrowth of 7 days at 100% confluence. Data represent the mean ± S.D. of n = 3
biological replicates.

mitochondrial dynamics and/or cristae remodeling associated with inactivation of OMA1-mediated processing
of the IM GTPase, OPA1. Of note, and in line with our observation in oma1−/− MEFs, the steady-state levels of the
key components of mitochondrial fusion (mitofusins MFN1 and MFN2, and long and short isoforms of OPA1)
and fission (DRP1) machinery remained largely unaltered in OM.21 (data not shown). We further investigated
the impact of OMA1 knockdown on 21MT-1 cell morphology by immunostaining of the actin cytoskeletal structures (Fig. 4B). Remodeling of actin cytoskeleton influences cell migration and invasion37. Genetic depletion of
OMA1 led to a substantial change in the 21MT-1 cell appearance, resulting in larger cell bodies and a stretched
morphology. Additionally, the OM.21 cells exhibited considerably more stress actin fibers traversing the cytoplasm than in the control 21MT-1 cells. Interestingly, these effects were not observed in OM.10 A cells. Akin
to oma1−/− MEFs [28], the bioenergetics profiling of OM.21 cells revealed these cells were unable to maximize
their respiration in response to mild uncoupling (Supplementary Fig. S4) and had significantly lower respiratory
control ratios when cultured in the respiration-enforcing medium containing 10 mM galactose. Moreover, just
like oma1−/− MEFs, OM.21 cells exhibited a marked increase in sensitivity to the glutaminase inhibitor BPTES;
all indicative of a bioenergetic deficit. These data suggest that loss of OMA1 promotes filopodia formation and
significant remodeling of the cell morphology and mitochondrial physiology in breast cancer cells.

Suppression of OMA1 increases proliferation and migration of metastatic breast adenocarcinoma cells. The proliferation and filopodia-like structures play a key role in cancer cell invasion38,39. Increased

appearance of these structures in OM.21 cells may indicate enhanced invasiveness of these cells and deregulation
of the cell cycle. We examined this hypothesis by immunostaining 21MT1, MCF10A, OM.21, and OM.10A cells
with Ki67 antibodies (Fig. 5A). Ki67, a nuclear protein, is a commonly used clinical marker to determine the
proliferative state of tumor cells3,4,40,41. Remarkably, the Ki67 expression was higher in the OM.21 cells, indicating
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Figure 4. Loss of OMA1 alters mitochondrial network organization and actin branching in 21MT-1 cells.
(A) Visualization of mitochondria in 21MT-1 and OM.21 cells. Image of MitoTrackerR Red CMXRos-stained
mitochondria in each respective cell type were captured using confocal fluorescent microscopy, Scale bar, 5 μm.
(B) Confocal fluorescent images of immunostained actin fibers in paraformaldehyde-fixed control and OM.21
cells show actin branching in the OMA1-depleted breast cancer cells, Scale bar, 5 μm.
that these cells are in a hyperproliferative state relative to normal 21MT-1 cells (Fig. 5A). Interestingly, OM.10 A
cells did not have any significant effect in the Ki67 expression as compared to control cells, indicating that this
phenomenon is specific to neoplasms.
To further interrogate the intriguing link between OMA1 silencing and the observed enhancement of cellular
migration, we examined the migratory potential of the metastatic breast cancer cells with normal and reduced
levels of the protease. To this end, a scratch was made in a sub-confluent cell monolayer in control and OM.21
cells and cells were allowed to migrate into the cell-free area. Loss of OMA1 resulted in significantly higher migration in 21MT-1 cells at both 24 and 48 hours compared to controls (Fig. 5B,C). In contrast, OMA1 depletion had
no effect on the migratory properties of non-cancerous MCF10A cells (Fig. 5D). Similar to the results observed
in 21MT-1 cells, abrogation of OMA1 resulted in significantly higher migration in 21PT cells at both 24 and
48 hours compared to controls (Supplementary Fig. S3E,F). These data suggest that loss of OMA1 function in
pre-metastatic breast adenocarcinoma cells could potentially facilitate the metastatic behavior of the tumor likely
via promoting the migration of breast cancer cells.

OMA1 deficiency augments invasiveness of breast cancer cells by inducing epithelial to mesenchymal transition. We next investigated whether depletion of OMA1 promotes EMT in tumor cells. EMT
Scientific Reports |

(2019) 9:14746 | https://doi.org/10.1038/s41598-019-49327-2

7

www.nature.com/scientificreports/

www.nature.com/scientificreports

Figure 5. OMA1 enhances proliferation and migration of 21MT-1 metastatic breast adenocarcinoma cells.
(A) Fluorescent images show Ki67 staining in MCF10A, OM.10A, 21MT-1, and OM.21 cells. Scale bar, 200 μm.
Histogram shows increase in Ki67 expression in OM.21 cells compared to control cells after 2 days in culture.
There is no significant difference in Ki67 expression in OM.10A and control MCF10A cells. At least three
independent experiments were conducted for each analysis. (B) Data illustrating the migration of cells out from
a confluent monolayer onto a featureless scratch or wound. Representative phase images of 21MT-1and OM.21
cells at 24 h and 48 h are shown. Scale bar, 20 μm. (C) Quantitative analysis of migratory properties of 21MT-1
and OM.21 cells. The extent of wound closure has been calculated as follows: % Wound Closure = [(Area at
0 h – Area at 24 or 48 h)/Area at 0 h] x 100%. Bars show mean data ± S.D. of 3 biological replicates; **p < 0.01,
***p < 0.001 by unpaired t-test. (D) Migratory properties of MCF10A and OM.10A cells were analyzed as in
Fig. 4C.
is a transient process during which epithelial cancer cells acquire molecular alterations that facilitate the loss of
epithelial features and gain a mesenchymal phenotype. This process is implicated during developmental stages and
carcinogenesis and is characterized by phenotypic and molecular changes leading to increased invasive and metastatic capabilities of cancer cells and drug resistance. When compared to control, OM.21 cells had a significantly
lower gene expression of epithelial markers, cytokeratin 19 (CK19) (1.5-fold) and MUC1 (2-fold), indicating a loss
in epithelial features of the cell (Fig. 6A). Reciprocally, OM.21 cells displayed substantially higher expression levels
of key mesenchymal markers: ZEB1 (3-fold), TWIST1 (3.5-fold), and fibronectin (FN) (4-fold) (Fig. 6A). We further examined the protein levels of some of the EMT markers by immunoblotting (Fig. 6B,C). A similar trend was
observed with a significant decrease in epithelial markers (E-cadherin, EpCAM) and an increase in mesenchymal
markers (Vimentin, FN, and TWIST1) in the OM.21 cells (Fig. 6B,C). We also observed similar trends in 21PT cells
where the loss of OMA1 resulted in significantly lower gene expression of epithelial markers, E-cadherin (4-fold)
and MUC1 (1.5-fold), indicating a loss in epithelial features of the cell (Supplementary Fig. S3G). Reciprocally,
OP.21 cells displayed substantially higher expression levels of key mesenchymal markers: Vimentin (3-fold),
SNAIL1 (3.5-fold), and fibronectin (FN) (2-fold) (Supplementary Fig. S3G). Overall, these results suggest a plausible role of OMA1 in suppressing aggressiveness and metastatic potential of these breast cancer cells.

Loss of OMA1 induces expression of canonical UPRmt genes in breast cancer cells.

To gain
insight into the potential mechanisms underpinning enhanced proliferative capacities of metastatic OM.21 cells,
we tested several potential scenarios. We ruled out the involvement of reactive oxygen species (ROS) and hypoxic
signaling as OM.21 cells exhibited neither elevated ROS production, nor appreciable stabilization of HIF1α, relative to control cell lines (data not shown). Similarly, no significant changes in the nuclear to mitochondrial DNA
ratio were observed in these cells – likely reflective of no alterations in mitochondrial proliferation and content.
Metabolic adaptation to promote survival or proliferation of cells with mitochondrial dysfunction could be
related to the mitochondrial unfolded protein response (UPRmt) [41]. We, therefore, tested if the loss of OMA1 results
in UPRmt activation. Quantitative real-time PCR and immunoblot analyses revealed that the transcript (Fig. 7A)
and protein (Fig. 7B) levels of several canonical UPRmt markers were significantly increased in OMA1-depleted
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Figure 6. OMA1 deficiency enhances invasiveness of breast cancer cells by inducing epithelial to mesenchymal
transition (EMT). (A) qRT-PCR analysis of the expression of EMT marker genes in 21MT-1 and OM.21
cells after 2 days in culture. The expression levels were normalized to GAPDH and to control cells. Data is
presented as mean ± S.D. from 3 biological replicates. *p < 0.05; **p < 0.01; ***p < 0.001 by Student’s t-test.
(B) Immunoblots showing protein expression of indicated EMT markers in 21MT-1 and OM.21 cells. (C)
Densitometry analysis of the respective bands normalized after loading control (GAPDH) correction. Control
cells grown served as control. Data are mean ± S.D.; n = 3 independent experiments; *p < 0.05; **p < 0.01;
***p < 0.001 by Student’s t-test.

21MT-1 cells, respectively. The enhanced UPRmt is consistent with a substantial decrease in the basal mitochondrial
membrane potential in OM.21 cells (Fig. 7C), which is likely associated with attenuation of mitochondrial protein
import and enhanced stabilization of UPRmt-mediating transcription factors such as ATF5 [42]. Akin to OM.21, we
observed decrease in mitochondrial membrane potential in oma1−/− MEFs as well (Supplementary Fig. S6). These
data suggest that loss of OMA1 leads to UPRmt activation and that sustained up-regulation of this signaling pathway
is a likely contributor to the enhanced invasiveness of metastatic breast cancer cells.

Discussion

In the present study, we have identified a novel role of the mitochondrial metallopeptidase OMA1 in the regulation of tumor progression in breast cancer cells. Our results show that depletion of OMA1 enhances the formation of filopodia, increased Ki67 expression, and induction of EMT markers. Concurrently, loss of OMA1 is
associated with alterations in mitochondrial protein homeostasis, as reflected by enhanced expression of canonic
mitochondrial unfolded protein response genes. These changes significantly increase migratory properties in
metastatic breast cancer cells, indicating that OMA1 plays a critical mechanistic role in suppressing metastatic
competence of breast tumors.
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Figure 7. Loss of OMA1 in 21MT-1 cells regulates mitochondrial unfolded protein response. (A) qRT-PCR
analysis showing increased expression of canonical UPRmt genes AFG3L2, CLPP, and HSPD1 in 21MT-1 and
OM.21 cells. n = 3 independent experiments. Error bars show mean values ± S.E.M.; **p < 0.01, by Student’s
t-test. (B) Representative immunoblots of extracts from 21MT-1 and OM.21 cells. Steady-state levels of the
AFG3L2 were detected with the respective antibodies. The GAPDH served as a loading control. The bottom
graphs show quantitative assessment of the immunoblots. Error bars, mean ± S.E.M.; n.s., **p < 0.01, by
Student’s t-test. (C) Representative flow cytometry histograms of 21MT-1 and OM.21 cells incubated with
50 nM TMRM under basal and CCCP-induced uncoupling conditions. 50,000 cells were assayed for TMRM
fluorescence in each experiment.

OMA1 is a conserved, stress-activated protease that resides in the IM and has been implicated in a number of
mitochondrial processes - most notably stress-triggered regulation of mitochondrial dynamics19,31. Recent reports
link OMA1 activity to the regulation of bioenergetic and metabolic outputs28,30,33, and demonstrated that loss of
OMA1 in mouse embryonic fibroblasts leads to enhanced compensatory glycolysis33. In line with these observations, OMA1-depleted 21MT-1 cells exhibit hallmarks of metabolic remodeling, as indicated by greatly increased
sensitivity of these cells to the glutaminase inhibitor, BPTES. Metabolic remodeling and formation of filopodia
are hallmarks of many invasive epithelial tumors14,38,42. Our subsequent analysis of the OMA1 stable knockdown
21MT-1 primary metastatic breast ductal carcinoma and 21 PT atypical ductal hyperplasia cells recapitulated
these observations, indicating a functional link between OMA1 and mechanisms that prevent EMT transition,
and related metastatic properties.
Our results implicate OMA1 as a potential modulating factor in actin cytoskeleton reorganization and
increased the formation of filopodia, which underscores the link between OMA1 function and suppression of
metastasis. Intriguingly, this effect is specific to metastatic 21MT-1 cells, but not the non-cancerous MCF10A
cells. The mitochondrial metallopeptidase OMA1 recently gained increased attention for its roles in the regulation of mitochondrial dynamics and metabolic remodeling19. This ATP-independent protease exists as an inner
membrane (IM)-anchored, homo-oligomeric complex that is largely dormant under normal physiological conditions. A range of mitochondrial homeostatic insults triggers OMA1 activation, which results in rapid proteolytic
processing of the IM GTPase, OPA1; which in turn propels fragmentation of the mitochondrial network, thereby
allowing mitochondria to adapt to changing physiological demands. A growing body of evidence indicates a
reciprocal link between mitochondrial morphology and cellular metabolic activity19.
Augmented cell motility is a fundamental aspect of increased metastasis in cancer43,44. Coordination between
the actin cytoskeleton and microtubules are crucial for cell polarization, shape changes, and migration43,44. The
actin cytoskeleton is believed to be the key driving force behind cell migration. At the leading edge of the cell,
actin is organized in a dense meshwork, which regulates filopodia formation and promotes forward movement.
In most cell types, migration is altered by interactions between the microtubule and actin cytoskeleton and it has
been shown that filopodia formation at the leading edge of migrating cells is crucial for chemoattractant-induced
breast cancer cell migration and invasion39,42. Our results suggest that OMA1 may be an important limiting factor
in early molecular events that regulate breast cancer cell migration and invasion; effects likely linked to the inability of OMA1-deficient cells to initiate remodeling of the mitochondrial network due to impaired proteolysis of
OPA145,46. In line with this idea, several studies reported links between the mitochondrial dynamics-controlling
GTPases and cellular signaling cascades of Ras47 and Notch48. Future studies are warranted to elucidate this
intriguing link.
We found that under our experimental conditions, OMA1 knockdown significantly augmented proliferation of the 21MT-1 cells, as judged by elevated Ki67 expression – a change not observed in non-tumorigenic
OMA1-depleted MCF10A cells. These data indicate the inverse correlation between OMA1 protein levels and
cell proliferation, and increased invasive behavior of breast cancer cells, suggesting that OMA1 may potentially
suppress the transition of cancer cells to metastates. It is noteworthy that our findings are in line with a recently
reported p53-dependent upregulation of OMA1 expression levels in gynecological cancers – a condition that
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augments cisplatin-induced death of these cells27. An important finding of the present study is the impact of
OMA1 on EMT in breast cancers. Loss of OMA1 expression significantly promoted the EMT of breast cancers
with a decrease in the epithelial markers and an increase in the mesenchyme markers (Fig. 1). Importantly, EMT
markers are strongly correlated to the progression of various tumors including breast to metastasis stage49,50. An
increase in the expression of TWIST1, ZEB1, and E-cadherin has been correlated with nearly every clinically
significant tumor type and has been shown to augment metastases34,36,50,51. One key point is that our observations
in the breast cancer cells may seem discordant from the MEF experiments. This is probably because MEF cells
are lacking the Tuberous Sclerosis Complex 2 (TSC2) gene, which alters PI3K-Akt signaling input to mTORC1,
thereby making it constitutively active52,53. Such hyperactive growth factor signaling may blunt related signaling
outputs and render MEF cells less sensitive to the effects of OMA1 depletion. Our results with highly confluent
MEF cell cultures in which mTORC1 signaling is attenuated are consistent with this idea54.
Depletion of OMA1 has been shown to be at least temporarily beneficial in post-mitotic cells such as neurons
or cardiomyocytes with initially compromised mitochondrial function20,55. However, our results suggest that the
loss of OMA1, and thus the ability to remodel mitochondrial shape and metabolic outputs, can be maladaptive in
rapidly dividing cells and promote neoplastic or enhance the metastatic potential of epithelial tumors. One candidate mechanism behind this effect is an elevated mitochondrial unfolded protein response. UPRmt has been shown
to promote glycolysis and maintain “stemness” of hematopoetic stem cells via the histone deacetylase, SIRT7, and
the transcriptional activator, NRF156. Elevated UPRmt may therefore reflect an attempt to metabolically compensate for an inability to remodel mitochondrial morphology due to OMA1 depletion. Based on our previous33 and
present data from experiments with oma1−/− MEFs, it is plausible that the observed UPRmt-promoted metabolic
effects are among the major contributors to EMT and subsequent enhancement of metastatic properties in OM.21
cells. Consistent with this postulate, recent studies have reported that stem cells57,58 as well as many epithelial tumors, including breast cancer7,10,59 display a glycolytic and/or glutaminolytic preference. These metabolic outputs
are also linked to other key biosynthetic pathways such as one-carbon metabolism, whose modulation may also
alter proliferative properties of a cell60. Additionally the idea of OMA1 levels as one of the significant predictors
to clinical progression of breast cancer is supported by the in silico analysis of TCGA breast cancer tumors (cBioPortal database) that revealed an unfavorable risk factor for survival of patients with breast cancer in low-OMA1
mRNA expressing subgroup, in contrast to the high OMA1-expressing subgroup with better survival (Fig. 1).
In conclusion, we report that down regulation of OMA1 expression in metastatic breast cancer cells and the
subsequent activation of UPRmt could form the basis for promoting malignancy and metastatic progression of
breast adenocarcinoma. These alterations are likely associated with metabolic remodeling towards enhanced
aerobic glycolysis and glutaminolysis and are expected to correlate with poor prognosis. We anticipate that the
reduced OMA1 expression-associated consequences need not be restricted to breast tumors and may possibly be
recapitulated in other cancer settings as well. Testing OMA1 protein levels in cancer patients may therefore serve
as a robust predictive marker for treatment responses and prognosis in development of personalized treatment
strategies. Elucidation of the exact role of OMA1 in regulating tumor biology and steps of EMT will help in the
development of improved anti-metastatic therapies that are useful against circulating metastatic breast cancer
cells and drug resistant cancer cells.

Materials and Methods

Generation of stable OMA1 knockdown cell lines. 21MT-1 and 21PT cell lines were a kind gift from
Dr. Vimla Band at the University of Nebraska Medical Center. This cell line was isolated from metastatic pleural effusion mammary tumor and atypical ductal hyperplasia specimens respectively61. The 21MT-1 and 21PT
cells were cultured in α-MEM media supplemented with 5% fetal bovine serum (FBS), 1% penicillin-streptomycin (PS), 1% L-glutamine, 20 mM HEPES, non-essential amino acids, sodium pyruvate (all stated reagents
were from Thermo Fischer Scientific), 12.5 ng/ml epidermal growth factor (EGF) and 1 µg/ml hydrocortisone
(both from Sigma-Aldrich). MCF10A (ATCC CRL-10317), human non-cancerous breast tissue cells were cultured in DMEM/F12 (Mediatech) and supplemented with 1% L-glutamine, 1% penicillin-streptomycin, 5%
horse serum, 0.1 ng/ml cholera toxin, 0.5 µg/ml hydrocortisone, 10 µg/ml insulin, and 0.02 ng/µl rhEGF (all from
Sigma-Aldrich). All cells were kept in aseptic conditions and grown in an incubator at 37 °C and 5% CO2. Cells
of interest were transfected with a set of OMA1 shRNA-expressing plasmids (Origene) using Lipofectamine 3000
reagent (Thermo Fisher Scientific). The cells were allowed to recover for 24 hours in fully supplemented DMEM/
F12 medium (10% FBS, 4mM L-glutamine, 4 mM glucose) without antibiotics. The medium was then replaced
with fully supplemented DMEM/F12 containing 3 μg/ml puromycin. Cells were selected in this medium until
a week after all the cells in the control wells (mock-transfected) were dead. Medium was replaced every 3 days.
Colonies of puromycin-resistant cells were then seeded in 25 cm2 cell culture flasks, and tested for decrease of
OMA1 expression by immunoblotting.
Cell viability assays. The wild type and oma1−/− mouse embryonic fibroblasts (24, kind gift from Dr. Carlos

Lopez-Otin, University of Oviedo) were seeded into 12-well plates at the density of 4 × 104 cells per well. DMEM
medium contained 10% FCS (Thermo Fisher Scientific) and L-glutamine (4 mM), as well as glucose (10 mM),
galactose (10 mM), with or without 10 µM bis-2-(5- phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES),
depending on experimental condition. Every 24 hours cells from one well per condition were trypsinized with
0.05% trypsin (Life Technologies), washed with Ca-, Mg- PBS, resuspended and counted in Countess Automated
Cell Counter (Life Technologies). The experiment was done in 4 biological replicates, with each replicate consisting of two technical replicates. Glucose, galactose, and BPTES were obtained from Sigma-Aldrich.

Imaging techniques. Phase images. Phase images were obtained for morphology of live cells assessment
using an Axiovert 40 CFL (Zeiss) and Progres C3 (Jenoptik) camera.
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Fluorescent imaging and actin staining. At the end of the treatment, cells were fixed with 4% paraformaldehyde
in PBS at room temperature for 20 min. Samples were permeabilized in 2% Triton X-100 for 15 min at room
temperature. Actin 488 Ready Probe (Life Technologies) was applied according to manufacturer instructions and
incubated on fixed cells at room temperature for 30 min. Nuclei were visualized with DAPI stain for 5 min, or
with Hoechst 33342 (Life Technologies) stain for 10 min, incubation at room temperature in the dark in a 1 µg/ml
solution. Images were obtained using Axiovert 40 CFL (Zeiss) and a Progres C3 (Jenoptik) camera with an X-Cite
series 120Q (Lumen Dynamics) lamp utilizing FITC or DAPI filter (Chroma).
Membrane potential measurement. Cells were seeded overnight in 6-well plates at 500,000 cells per well. Prior
to the experiment, cells were either treated with vehicle (DMSO) or CCCP (final concentration 2uM) for 1 hr.
Following the treatments, cells were trypsinized with 0.05% trypsin, washed 3x with PBS and resuspended in
1 ml PBS for staining. Cells were stained on ice in 50 nM TMRM (Sigma) for 15 min, and subsequently assayed on
Cytek DxP10 flow cytometer (Cytek Biosciences). TMRM fluorescence was measured using 561 nm excitation,
and 580/20 nm emission; 50,000 cells were assayed in each experiment. Results were analyzed and plotted using
FlowJo 10 software (FlowJo).
Mitochondrial imaging. Mitochondrial morphology was assessed using MitoTrackerR Red CMXRos (Life
Technologies) staining according to manufacturer’s instructions. Briefly, 24 hr following the seeding of cells,
the old culture media was removed and replaced with serum-free, phenol red-free DMEM containing 300 nM
MitoTrackerR probe and incubated at 37 °C for 30 min. Cells were then washed three times with warm 1X PBS
and serum free, phenol-red free DMEM was added for viewing with an Olympus FV500 Inverted Confocal
Microscope.
Quantitative real-time PCR. qRT-PCR was performed using standard qRT-PCR program on ABI 7900HT
qRT-PCR cycler (Applied Biosystems), with validated qRT-PCR primers (Realtimeprimers.com). Expression
data for AFG3L2, CLPP, SPG7 and HSPD1 were normalized using qRT-PCR for Actin B. SYBR-Green qPCR mix
was obtained from Life Technologies. The experiment was done in 3 biological replicates, each consisting of 4
technical replicates.
Western blotting. Whole cell lysates from cell cultures was prepared using RIPA buffer (1X PBS containing 1%
IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 1 mM phenylmethylsulfonyl
fluoride (PMSF) and protease inhibitor cocktail). Cells were washed three times with ice cold 1X PBS, lysed in
RIPA buffer on ice for 10 min. Samples were then centrifuged at 10,000 × g for 20 min at 4 °C, supernatant was
transferred to 0.2 μM microcentrifuge filters (ThermoFisher Scientific), and centrifuged at 10,000 × g for 10 min
at 4 °C to collect clear cell lysate. Protein concentrations were determined using Coomassie Plus Assay reagent
(Pierce). 10 μg of total protein was separated by 7.5% SDS-polyacrylamide gel electrophoresis and transferred
to Immobilon P membranes (Millipore) using transfer buffer (25 mM Tris, 192 mM glycine, 10% methanol).
Membranes were blocked with 5% skimmed milk for 2 h at room temperature (RT) followed by incubations
with either anti-EMT markers IgG panel (GeneTex GTX300096, 1:1000), or anti-OMA1 IgG (Aviva Systems
Biology ARP52818_P050, 1:1000), or anti-AFG3L2 IgG (Aviva Systems Biology ARP46780_P050, 1:1000), or
anti-HSPD1 (Aviva Systems Biology AVARP09014_P050, 1:1000), or anti-HIF1α IgG (Aviva Systems Biology
ARP38054_P050, 1:1000) or anti-GAPDH IgG (Millipore ABS16, 1:4000) for overnight at 4 °C. Membranes were
then incubated with HRP-linked goat anti-rabbit IgG (Santa Cruz Biotechnology sc2054, 1:4000) for 1 h at RT.
The antigen-antibody complex was detected using ECL and the images were captured on autoradiography films
(ECL Hyperfilm, Pierce). The immunoreactive signals were quantified by densitometry using Image Studio Lite
Software v.4.0 (LI-COR Biosciences).

™

In vitro migration assay. 21MT-1, 21PT, or MCF10A cells (control and shOMA1) were plated into 12 well plates
as confluent monolayers. Three vertical scratches were made per well (using a 10 µl pipette tip), and cell debris
was washed away with 1X PBS prior to capturing the zero time photos. Additional photos were taken at 24 and
48 hours time points. The cells were supplemented with complete 21MT-1 media for the entire migration assay.
ImageJ software was used to quantify the scratch width (arbitrary units) changes at each time point. A total of 27
scratch width data points were taken for each sample type at each time point (3 scratches per well x3 pictures per
scratch x3 biological duplicates per sample type).
Bioenergetic profiling. Metabolic quantification of cells was measured using a Seahorse XFe24 Extracellular Flux
Analyzer (Seahorse Bioscience) in XFe24 microplates. Cells were seeded at the density of 5 × 104 cells per well
24 hours before the experiment in Seahorse medium (Agilent Technologies/Seahorse Bioscience) supplemented
with L-glutamine (4 mM), as well as glucose (10 mM), galactose (10 mM), BPTES (10 µM) and pyruvate (2 mM),
depending on experimental condition. After 24 hours, the cells were washed twice and supplemented with 0.5 ml
fresh Seahorse medium containing L-glutamine (4 mM), glucose (10 mM), galactose (10 mM), BPTES (10 µM),
and pyruvate (2 mM), depending on experimental condition, and kept for 1 hour in non-CO2 incubator at 37 °C.
The OCR was measured under basal conditions and addition of olygomycin (1 µM), FCCP (1 µM), and rotenone/
antimycin A (0.5 µM). Measurements were performed using standard Mito Stress protocol on XFe24 Extracellular
Flow Analyzer (Agilent Technologies). Oligomycin, FCCP, and rotenone/antimycin A were obtained as a part
of Mito Stress Kit (Agilent Technologies/Seahorse Bioscience). Glucose, galactose, BPTES, L-glutamine, and
pyruvate were obtained from Sigma-Aldrich. Extracellular acidification rates (ECAR) were measured using the
Seahorse XF Cell Glyco Stress Test using successive injections of glucose (10 mM), oligomycin (1 µM), and 2-DG
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(50 mM). Three measurements were taken before and after each injection and mixing cycle. Rates were normalized to non-glycolytic acidification rate by well. The experiment was done in 4 biological replicates, with each
replicate consisting of 3–4 technical repeats per condition.
Bioinformatics and statistical analyses. Expression of OMA1 mRNA, evaluated from RNA-Seq data, available
for breast cancer tumors, was downloaded from TCGA provisional dataset and UCSC Xena websites. OMA1
mRNA expressed as OMA1 mRNA expression, Batch Normalized/Merged from Illumina HiSeq_RNA SeqV2
syn4976739, generated by TCGA, was plotted using the Box and Whisker plot62. The Box and Whisker plot
depicts normal distribution of OMA1 mRNA and determines the median and quartiles in a statistical population.
Utilizing the TCGA data, Kaplan-Meier survival curves were generated by dividing tumors into
non-overlapping upper and lower groups based on OMA1 mRNA values up to 25th percentile as low and above
25th as high31,32. Log-rank (Mantel-Cox) statistical test was used to compare the survival distribution of these two
samples.
Statistical analyses were performed using Microsoft Excel 2013 Analysis ToolPak and GraphPad Prism 4 software. In each case, the results of at least three independent experiments were analyzed using one-way ANOVA or
Student’s t-test. The p values <0.05 were considered statistically significant.

One-sentence summary. Breast cancer patients with low mitochondrial protease OMA1 expression have a
shorter survival time; depletion of OMA1 enhances formation of filopodia, increases cell proliferation, and induces
epithelial-mesenchymal transition, thereby stimulating migratory properties of metastatic breast cancer cells.
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